The literature was reviewed to determine the impact of Medicare supplement insurance (i.e. Medigap) on the Medicare program with respect to access, utilization, outcomes, costs, and drug compliance. Additionally, we discuss a new program to improve pharmaceutical utilization for Medigap enrollees. METHODS: We conducted a literature search using PubMed, looking for peer-reviewed articles that compared access, utilization, outcomes and costs between enrollees with Medicare fee-for-service coverage alone to those with Medigap. Additional searches focused on differences in pharmacological compliance, for those with and without drug coverage, among the two groups. Finally, we searched for pharmacy compliance programs offered through supplement insurance plans. RESULTS: Twenty-seven articles met our search criteria. The literature suggests Medicare Supplement Insurance can be costeffective, that it is correlated with better access to health care services, and may result in higher utilization of preventive services than would be the case without such coverage. Also, the type of supplement insurance did not signifi cantly infl uence prescription drugs utilization among Medicare enrollees. No articles found discussed any current efforts to manage the pharmaceutical treatment of Medicare Supplement Insurance enrollees. CONCLUSIONS: Medigap programs have not historically managed their enrollees like Medicare Advantage plans have done. In particular, the literature suggests there is much room for improvement in pharmacy management for all Medicare populations, including those enrolled in Medigap plans. This has led AARP and UnitedHealth Group to offer a pharmacological compliance program, with disease management and case management programs, for their AARP Medicare Supplement Insurance enrollees, beginning in 2009. Results from this care management effort will help tailor models for more ways to better manage the care for fee-for-service Medicare enrollees with supplement coverage.
the year following index the same HSDD group incurred total health care costs that were $897 (p 0.001) higher. Drivers of increased health care costs in the year prior to index diagnosis included inpatient services (21.1% of the cost difference), outpatient medical services (45.1% of the difference) and prescription medications (17.3%).
During the year following index diagnosis, outpatient medical services accounted for 53.4% of the cost difference, while prescription medications accounted for 33.3%. CONCLUSIONS: Women with HSDD utilize signifi cantly more health care services and incur higher overall costs before and after diagnosis compared with women without a diagnosis of sexual dysfunction. While outpatient medical services were the largest component of overall health care costs for patients with HSDD, prescription medication costs were also signifi cantly higher than matched controls.
PIH22 ESTIMATING DIRECT COST OF VAGINITIS IN TURKEY
Tulunay FC y 1 , Malhan S 2 1 Ankara University Medical School, Ankara, Turkey, 2 Baskent University, Ankara, Turkey OBJECTIVES: To determine the annual direct cost of treatment of vaginitis in Turkey. METHODS: A consensus panel approach was implemented in order to defi ne the vaginitis management pattern and relevant resource utilization. The panel consisted of 11 gynecologists, affi liated with the existing patterns of outpatient health care settings. Cost analysis was based on the estimation of 1 year direct cost of treatment, based on 2008 fees and prices, expressed in dollars. RESULTS: Total cost of vaginitis treatment was found to be $81.6 per patient. This cost covered partner expenditures. The disbursement included outpatient clinic fees and pharmacotherapy. The laboratory tests were included in the outpatient clinic fees according to new Social Security Institution (SSI) regulations. CONCLUSIONS: Altough the prevalence and causes of vaginitis are uncertain, in part because the condition is so often self-diagnosed and self-treated, women often seek medical care for vaginal complaints. SSI may have to reimburse vaginitis treatment more than once for a woman in a year. Therefore, the SSI should know the cost of vaginitis treatment in order to make a budget plan among other treatments.
PIH23 A SYSTEMATIC REVIEW OF THE COST OF FALLS IN OLDER ADULTS: AN INTERNATIONAL PERSPECTIVE
Davis JC J 1 , Robertson MC 2 , Ashe MC 1 , Khan KM 1 , Marra CA 1 1 University of British Columbia, Vancouver, BC, Canada, 2 University of Otago, Dunedin, New Zealand OBJECTIVES: To compare international estimates for direct and indirect cost of falls among older adults. We compared both the total cost of falls and the mean cost per individual fall. METHODS: We conducted a systematic review of peer reviewed journal articles reporting estimates for the cost of falls in older adults. We searched for papers published between 1945 and July 2008 in MEDLINE, PUBMED, EMBASE, CINAHL, Cochrane Collaboration and NHS EED and identifi ed papers that included a cost analysis of falls in older adults. We report cost of falls in the manuscripts' currency and in US dollars at 2008 prices, cost items measured, perspective, time horizon and sensitivity analysis. We assessed the quality of the studies using a selection of questions from Drummond's Checklist. RESULTS: Twenty-two studies met our inclusion criteria and these included 11 studies from the United States, three from Australia, four from Europe and two each from New Zealand and the UK. There were distinct variations across studies with respect to: viewpoint of the analysis, defi nition of falls, identifi cation of all important and relevant cost items and time horizon. Our quality assessment indicated that only two studies reported a sensitivity analysis and only four studies identifi ed the viewpoint of their economic analysis. A prospective cohort study indicated the total one-year cost of all fall related injuries in 1995 was US $88.36 billion (at 2008 prices). CONCLUSIONS: The cost of falls depended largely on the time horizon over which costs were collected, cost items collected and defi nition of falls. To accurately compare costs among countries, we need a consensus on defi nition of fall related outcome measures and cost items.
PIH24 AN INVESTIGATION OF THE EFFECTS OF GENDER, RACE, AGE, AND OTHER DESCRIPTIVE VARIABLES ON THE LENGTH OF HOSPITALIZATION AND TOTAL HOSPITALIZATION CHARGES ACCRUED BY PEDIATRIC INPATIENTS AFFLICTED WITH PHARYNGITIS
Perry JD y J University of Louisville, Louisville, KY, USA OBJECTIVES: Pharyngitis is a disease that commonly affects patients from various ages, genders, and ethnicities. This investigation will serve as an exploratory analysis of basic pediatric inpatient descriptors, and their relationships with respect to hospitalization charges, length of hospitalization, and the contraction of Pharyngitis. METHODS: In this study, length of hospitalization and hospitalization charges are analyzed with respect to patient age, gender, and race. Logistic and linear regressions are included to show relationships among independent variables, descriptive variables, and the contraction of Pharyngitis. The Statistical Analysis Software (SAS), Enterprise Guide version 4.0, was utilized in the data analysis. The data are from the 2005 National Inpatient Sample and contained 4169 patients with Pharyngitis and a control group of 4200 patients. RESULTS: It was shown that on average, White, male, Pharyngitic patients 0-3 years old pay the least in hospitalization charges while female patients of Asian/Pacifi c Islander descent 12-15 years old pay the most in hospitalization charges. White, female patients 0-7 years old have the shortest hospitalization periods while male patients of Native American descent 12-18 years old have the longest average hospital visits. In total, several variables, including specifi c procedures and diagnoses, such as Volume Depletion and Fever, are seen as statistically signifi cant in determining the likelihood of a patient contracting Pharyngitis. Additional results were derived from a linear regression, which contains analysis specifi c to length of hospitalization and hospitalization charges. CONCLUSIONS: This investigation provides only a general overview of the statistical relationships contained within a data set of pediatric inpatients primarily affl icted with the disease, Pharyngitis. Because of the nature of the disease, it should be noted that further investigations should be conducted to verify any relationships found to be statistically signifi cant.
PIH25 DIRECT COST OF INFERTILITY TREATMENT IN TURKEY
Malhan S 1 , Tulunay FC 2 1 Baskent University, Ankara, Turkey, 2 Ankara University, Ankara, Turkey OBJECTIVES: Infertility is a vital problem for men and woman in Turkey. It decreases the quality of life more than many chronic diseases. The infertility treatment is reimbursed by the government, only twice in a life-time and only if you are a woman younger than 39 years old. Infertility treatment can be considerably long, and many times, the couples need to try more than twice. The government reimburses €656 (1240 YTL) for each treatment. The objective of this study was to calculate the cost of infertility treatment at a University Hospital. METHODS: An expert panel composed of obstetricians in Osman Gazi University developed an infertility clinical protocol for this particular university. This protocol was used to calculate the cost of an infertility intervention. A third-party payer perspective to estimate cost of this intervention was chosen. Therefore, to estimate the total cost of an infertility intervention, the offi cial price lists established by the Social Security Organization was used. RESULTS: Specialists developed three clinical pathways; antagonist protocol, short and long protocol. Total cost of the antagonist protocol was 1079 Euro, for the short protocol this was €1117, and the long protocol €1059. If the couple had to try all 3 protocols, they had to pay €3255, and the government reimbursed only 1312 Euro. This meant that the couple had to pay €1943. CONCLUSIONS: The Social Security Organization extended the prospective payment system (fi xed prices for treatment) coverage for hospital services including fertility treatments, in 2003. We found out that, fi xed prices determined by SSO do not refl ect actual costs of the services. Due to the fact that the cost of services delivered in university hospitals are higher than other hospitals, university hospitals should develop cost saving strategies to provide fertility treatment services.
PIH26 THE ECONOMIC IMPACT OF SINGLETON, TWIN AND MULTIPLE GESTATION PREGNANCIES IN ALBERTA Chuck A, Yan C
Institute of Health Economics, Edmonton, AB, Canada OBJECTIVES: The increasing rate of multiple pregnancies, which are associated with greater health resource use, has been attributed to the broad availability and use of assistive reproductive technologies (ARTs). The advocate of publicly funding ARTs argues that, if publicly funded, the government could consider mandating the number of embryos transferred per IVF cycle so as to contain the health care cost. The study was to investigate the association between multiple gestations and low birth weight (LBW) infants and to explore the impact on health resource utilization and costs. METHODS: The population cohort comprised mothers and infants born between April 1, 2004 and March 31, 2005 in Alberta, Canada. The study considered costs and resource utilization from birth to 1 year for infants and from pregnancy to 3 months post partum for mothers. Information related to hospital costs was collected from Alberta hospital inpatient database, while that related to physician services from the Alberta Health Care Insurance Plan. A logistic regression was employed to determine the likelihood that twins and higher order multiples (HOM) was born LBW, compared with singletons. Linear regressions were used to estimate the impact of multiple births and LBW on resource utilization and costs. RESULTS: A cohort of 36,158 mothers and 36,767 infants were included in the study. The logistic regression indicated that, compared to singletons, twins and HOM were 43.8% and 90% more likely to be born LBW respectively, while HOM were 46.2% more likely to be born LBW in comparison with twins. The mean total cost of LBW twins and LBW HOM were respectively, 5.88 ($14,253 vs. $2,425) and eight times ($19,435 vs. $2,425) greater than that of NBW singletons. CONCLUSIONS: This study suggested that multiple births were associated with higher likelihood of being born LBW and consequently resulted in more resource utilization.
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PIH27 THE IMPACT ON ADHERENCE AND FORMULARY PERFORMANCE METRICS OF ALLOWING MEMBERS TO CHOOSE EITHER MAIL OR RETAIL PHARMACY FOR RECEIVING 90-DAY SUPPLY MAINTENANCE MEDICATIONS
Hutchins DS 1 , Liberman JN 2 , Bradly A y 3 1 CVS Caremark Corporation, Scottsdale, AZ, USA, 2 CVS Caremark Corporation, Hunt Valley, MD, USA, 3 CVS Caremark Corporation, Woonsocket, RI, USA OBJECTIVES: To compare medication adherence for patients new to 90-day supply prescriptions under a new pharmacy benefi t where pricing is equivalent, allowing members to choose either retail or mail pharmacy as their preferred distribution channel. METHODS: Claims (n 168,381) submitted between Apri, 1, 2008 and December 31, 2008 for an employer after it began offering the same price on 90-day retail and mail maintenance prescriptions were used to calculate Medication Possession Ratio (MPR), Generic Dispensing Rate (GDR), Generic Substitution Rate (GSR), and Preferred Brand Dispensing (PBDR) for patients impacted by the benefi t. GDR, GSR, and PBDR were calculated for all claims with a 90-day supply. MPR was calculated for all patients who were eligible 180 days before and after their fi rst 90-day prescription between April 1 and June 30, 2008 for each maintenance class, using that fi rst prescription and any within the subsequent 180 days. Overall metrics and those for select classes with suffi cient sample size are presented. RESULTS: The average MPR, across all classes, was 80% for retail dispensed prescriptions and 78% for mail. Among six high-volume classes, the average MPR was 82% at retail and 81% at mail, with MPRs for individual classes ranging from 75% (PPIs) to 89% (ACEs and Anticonvulsants) for retail-dispensed and 74% (SSRIs) to 85% (ACEs) for mail-dispensed. When comparing retail and mail dispensed prescriptions, GDR (57% vs. 56%), GSR (99% vs. 99%), and PBDR (86% vs. 86%) were nearly identical. CONCLUSIONS: When out-of-pocket costs and days supply per prescription are identical, adherence rates and related formulary performance metrics for mail and retail-dispensed maintenance medications appear essentially similar in early results. These pilot results will need to be confi rmed as more payers adopt this benefi t design and longer follow-up periods improve adherence measurement precision.
